RxDoctor Payments Data

Bancy Mwangi

Family · Mishawaka, INNPI 1427828854

Payments from drug & device makers

$1,192in general payments, 2019–2025

Across 44 payments — averaging $27.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$455
  • Organogenesis Inc.$150
  • Neurocrine Biosciences, Inc.$140
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$80
  • Scilex Pharmaceuticals Inc.$78
  • Lundbeck LLC$63
  • plus $226 from 7 others

What the payments were for

  • Food & beverage$1,192100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,192 in reported general payments places this provider in the 70th percentile of 4,392 family providers in Indiana.

See all family providers in Indiana

Medicare billing

Part B allowed, 2024
$23,017
Medicare patients
87
Services billed
341

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate26$30,524
Xtampza ErOxycodone Myristate19$16,657
ZtlidoLidocaine19$7,215
BelsomraSuvorexant16$7,034
Lidocaine41$3,820
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen196$3,496
Pregabalin153$2,546
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen129$2,151
Tizanidine Hcl178$2,112
Tramadol Hcl-AcetaminophenTramadol Hcl/Acetaminophen121$1,798
Gabapentin129$1,267
Diclofenac Sodium118$986
Topiramate127$612
Celecoxib38$521
Methadone Hcl29$488

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt$50$30,52426 claims
Collegium Pharmaceutical, Inc.Xtampza Er$50$16,65719 claims
Scilex Pharmaceuticals Inc.Ztlido$78$7,21519 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,392 family providers in Indiana.

Other family in Mishawaka

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →